Discover.
Launch.
Build.
Transform.
● Recent Highlights
Sage Therapeutics
Sage and Biogen announced FDA approval for ZURZUVAE™ (zuranolone) in the treatment of postpartum depression (PPD). ZURZUVAE™ is a 14-day, rapid-acting, once-daily, oral treatment in adults with PPD. Mental health conditions are the leading cause of maternal mortality with PPD among the most common complications during and after pregnancy and ZURZUVAE™ is a fast-acting new option that can address this highly unmet medical need.
Rapport Therapeutics
Rapport is dedicated to the discovery and development of precision medicines for neurological disorders.
Portfolio
CARGO Therapeutics
CARGO Therapeutics is outsmarting cancer to deliver more cures.
CARGO Therapeutics
bluebird bio
bluebird bio received FDA accelerated approval for SKYSONA® (elivaldogene autotemcel) gene therapy for early, active cerebral adrenoleukodystrophy (CALD). SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease.
bluebird bio
Living our core values.
One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion in the life sciences sector.
Learn more
Terremoto Biosciences
Terremoto is harnessing covalent chemistry to discover and develop small molecule medicines.
Terremoto Biosciences
MyoKardia
Bristol Myers Squibb (BMS) received approval from the U.S. FDA for Camzyos® (mavacamten). Camzyos, the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive hypertrophic cardiomyopathy, was originally developed by Third Rock portfolio company, MyoKardia, which was acquired by BMS in 2020.
bluebird bio
bluebird bio and Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for Abecma® (idecabtagene vicleucel) as the first CAR T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma.
bluebird bio